Literature DB >> 28869986

Diagnostic Accuracy of Novel and Traditional Rapid Tests for Influenza Infection Compared With Reverse Transcriptase Polymerase Chain Reaction: A Systematic Review and Meta-analysis.

Joanna Merckx1, Rehab Wali1, Ian Schiller1, Chelsea Caya1, Genevieve C Gore1, Caroline Chartrand1, Nandini Dendukuri1, Jesse Papenburg1.   

Abstract

BACKGROUND: Rapid and accurate influenza diagnostics can improve patient care.
PURPOSE: To summarize and compare accuracy of traditional rapid influenza diagnostic tests (RIDTs), digital immunoassays (DIAs), and rapid nucleic acid amplification tests (NAATs) in children and adults with suspected influenza. DATA SOURCES: 6 databases from their inception through May 2017. STUDY SELECTION: Studies in English, French, or Spanish comparing commercialized rapid tests (that is, providing results in <30 minutes) with reverse transcriptase polymerase chain reaction reference standard for influenza diagnosis. DATA EXTRACTION: Data were extracted using a standardized form; quality was assessed using QUADAS-2 (Quality Assessment of Diagnostic Accuracy Studies 2) criteria. DATA SYNTHESIS: 162 studies were included (130 of RIDTs, 19 of DIAs, and 13 of NAATs). Pooled sensitivities for detecting influenza A from Bayesian bivariate random-effects models were 54.4% (95% credible interval [CrI], 48.9% to 59.8%) for RIDTs, 80.0% (CrI, 73.4% to 85.6%) for DIAs, and 91.6% (CrI, 84.9% to 95.9%) for NAATs. Those for detecting influenza B were 53.2% (CrI, 41.7% to 64.4%) for RIDTs, 76.8% (CrI, 65.4% to 85.4%) for DIAs, and 95.4% (CrI, 87.3% to 98.7%) for NAATs. Pooled specificities were uniformly high (>98%). Forty-six influenza A and 24 influenza B studies presented pediatric-specific data; 35 influenza A and 16 influenza B studies presented adult-specific data. Pooled sensitivities were higher in children by 12.1 to 31.8 percentage points, except for influenza A by rapid NAATs (2.7 percentage points). Pooled sensitivities favored industry-sponsored studies by 6.2 to 34.0 percentage points. Incomplete reporting frequently led to unclear risk of bias. LIMITATIONS: Underreporting of clinical variables limited exploration of heterogeneity. Few NAAT studies reported adult-specific data, and none evaluated point-of-care testing. Many studies had unclear risk of bias.
CONCLUSION: Novel DIAs and rapid NAATs had markedly higher sensitivities for influenza A and B in both children and adults than did traditional RIDTs, with equally high specificities. PRIMARY FUNDING SOURCE: Québec Health Research Fund and BD Diagnostic Systems.

Entities:  

Mesh:

Year:  2017        PMID: 28869986     DOI: 10.7326/M17-0848

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  78 in total

1.  Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa.

Authors:  Timothy M Uyeki; Henry H Bernstein; John S Bradley; Janet A Englund; Thomas M File; Alicia M Fry; Stefan Gravenstein; Frederick G Hayden; Scott A Harper; Jon Mark Hirshon; Michael G Ison; B Lynn Johnston; Shandra L Knight; Allison McGeer; Laura E Riley; Cameron R Wolfe; Paul E Alexander; Andrew T Pavia
Journal:  Clin Infect Dis       Date:  2019-03-05       Impact factor: 9.079

Review 2.  Laboratory Tests for COVID-19: A Review of Peer-Reviewed Publications and Implications for Clinical UIse.

Authors:  Daniel Shyu; James Dorroh; Caleb Holtmeyer; Detlef Ritter; Anandhi Upendran; Raghuraman Kannan; Dima Dandachi; Christian Rojas-Moreno; Stevan P Whitt; Hariharan Regunath
Journal:  Mo Med       Date:  2020 May-Jun

Review 3.  The Drift in Molecular Testing for Influenza: Mutations Affecting Assay Performance.

Authors:  Kathleen A Stellrecht
Journal:  J Clin Microbiol       Date:  2018-02-22       Impact factor: 5.948

4.  Association of physician experience with a higher prescription rate of anti-influenza agents in low-risk patients.

Authors:  Koji Nakajima; Hiroyuki Akebo; Yukio Tsugihashi; Hiroyasu Ishimaru; Ryuichi Sada
Journal:  Intern Emerg Med       Date:  2021-01-02       Impact factor: 3.397

5.  Profile of the Alere i Influenza A & B assay: a pioneering molecular point-of-care test.

Authors:  Hongmei Wang; Jikui Deng; Yi-Wei Tang
Journal:  Expert Rev Mol Diagn       Date:  2018-04-24       Impact factor: 5.225

6.  Validation of a New Rapid Detection Test for Detection of Neisseria meningitidis A/C/W/X/Y Antigens in Cerebrospinal Fluid.

Authors:  Cyrille H Haddar; Aude Terrade; Paul Verhoeven; Berthe-Marie Njanpop-Lafourcade; Mireille Dosso; Fati Sidikou; Ali Elhaj Mahamane; Jean-Pierre Lombart; Aziza Razki; Eva Hong; Alain Agnememel; Evelyne Begaud; Yves Germani; Bruno Pozzetto; Muhamed-Kheir Taha
Journal:  J Clin Microbiol       Date:  2020-02-24       Impact factor: 5.948

7.  Clinical Impact of Rapid Point-of-Care PCR Influenza Testing in an Urgent Care Setting: a Single-Center Study.

Authors:  Robert C Benirschke; Erin McElvania; Richard B Thomson; Karen L Kaul; Sanchita Das
Journal:  J Clin Microbiol       Date:  2019-02-27       Impact factor: 5.948

Review 8.  Detection of Influenza A and B Viruses and Respiratory Syncytial Virus by Use of Clinical Laboratory Improvement Amendments of 1988 (CLIA)-Waived Point-of-Care Assays: a Paradigm Shift to Molecular Tests.

Authors:  Marwan M Azar; Marie L Landry
Journal:  J Clin Microbiol       Date:  2018-06-25       Impact factor: 5.948

9.  Comparison of Six Sample-to-Answer Influenza A/B and Respiratory Syncytial Virus Nucleic Acid Amplification Assays Using Respiratory Specimens from Children.

Authors:  Dithi Banerjee; Neena Kanwar; Ferdaus Hassan; Cynthia Essmyer; Rangaraj Selvarangan
Journal:  J Clin Microbiol       Date:  2018-10-25       Impact factor: 5.948

10.  Are Rapid Influenza Antigen Tests Still Clinically Useful in Today's Molecular Diagnostics World?

Authors:  Valentina K Trombetta; Yvonne L Chan; Matthew J Bankowski
Journal:  Hawaii J Med Public Health       Date:  2018-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.